Author

B. Kochupurakkal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. D. D'Andrea· 2 shared G. I. Shapiro· 2 shared A. Farkkila· 1 shared A. G. Waks· 1 shared A. Li· 1 shared A. Syed· 1 shared B. S. Blagg· 1 shared C. E. Dunn· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. D. D'Andrea

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivMay 23, 2020

Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors

J. Zhou, C. Gelot, C. Pantelidou…·A. D. D'Andrea

The paper identifies Novobiocin as a POLθ inhibitor that selectively kills HR-deficient tumors, including those resistant to PARP inhibitors.

DOI 10.1038/s43018-021-00203-x

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivNov 10, 2019

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

A. G. Waks, O. Cohen, B. Kochupurakkal…·N. Wagle

This study identifies genomic reversion and increased DNA end resection as mechanisms of resistance to PARP inhibitors and platinum in BRCA1/2-mutant metastatic breast cancer, with RAD51 foci as a potential biomarker.

DOI 10.1016/j.annonc.2020.02.008

humanwhole-exome sequencing

𝕏 PostBluesky